BG00010 (Neublastin)

DRUG2 trials

Sponsors

Biogen

Conditions

Sciatica

Phase 1

Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants

CompletedNCT00961766

Start: 2009-08-31End: 2012-02-29Updated: 2014-10-28

Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.

CompletedNCT01405833

Start: 2011-07-31End: 2012-09-30Updated: 2014-09-09

Related Papers

First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica

PLoS ONE2015-05-1125 citations